Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay

Kline, Richard L.; McNairn, Denise; Holodniy, Mark; Molé, L; Margolis, Dan; Blattner, William A.; Quinn, Thomas C.

doi:10.1128/jcm.34.11.2650-2653.1996

Cited by 21 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, particle agglutination involves the adhesion of particles coated with antigens or antibodies; in the presence of HIV antigens or antibodies, particles agglutinate resulting in visually illustrated reactivity (Hong et al ). Furthermore, recombinant immunoblot assays utilize recombinant viral antigens which are visually illustrated as bands on nitrocellulose strips (Kline et al ; Mas et al ).…”

Section: Resultsmentioning

confidence: 99%

Human immunodeficiency virus in cadavers: A review

2019

View full text Add to dashboard Cite

Millions of people are infected with human immunodeficiency virus (HIV); however, limited research focuses on post-mortem HIV detection. Post-mortem HIV testing is vital because medical records are not always available, and the HIV status can be unknown. The aims of this study were to review the available literature and determine the most efficient HIV test for post-mortem samples, the optimal tissue or bodily fluid to be tested, and the duration that HIV remains reliably detectable. A literature search was conducted using PubMed and Google Scholar. Terms were related to HIV (HIV detection, HIV testing, HIV prevalence) and deceased individuals (post-mortem, cadaver, deceased, organ donor). Inclusion criteria included English studies, or articles with at least an English abstract, while review articles were excluded. From this literature search, 43 studies were applicable. These studies most commonly used enzyme-linked immunosorbent assay and Western blot as screening and confirmation tests, respectively. As for the optimal tissue or bodily fluid, serum remained the golden standard, while testing skin seemed promising. HIV remains detectable in the body up to 58 days after death, although few studies tested samples after 48 h. Knowledge of the HIV status can be beneficial in the case of accidental exposure and can create a range of possible research opportunities on the effects of HIV in different organ systems. This review outlined several gaps in the current literature and future studies should investigate these gaps because this information can be relevant to numerous professions. Clin. Anat. 32:603-610, 2019.

show abstract

Section: Resultsmentioning

confidence: 99%

Human immunodeficiency virus in cadavers: A review

2019

View full text Add to dashboard Cite

show abstract

“…The 73 sera that yielded discordant CME and Peptilav results were further investigated by two LIAs (INNO-LIA and RIBA HIV-1/2) that have been evaluated and shown to be reliable for type-specific HIV serodiagnosis (10,20). Of the 45 sera that were scored as HIV-2 antibody positive by Peptilav but HIV-D antibody positive by CME, all were weakly reactive by the Wellcozyme assay (OD ratio Ͻ3.0) ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Peptilav 1-2 (Sanofi Diagnostics Pasteur), which recognizes antibodies to the transmembrane glycoproteins of the two viruses (gp41 for HIV-1 and gp36 for HIV-2), and the INNO-LIA HIV confirmation test (Innogenetics, Ghent, Belgium), which uses the HIV-1 synthetic peptide antigens p17, p24, p31, gp41, and gp120 and the HIV-2 antigens gp36 and gp105 (20) were used. Lastly, a strip immunoassay (RIBA HIV-1/HIV-2 SIA), a research LIA kit from Chiron (Emeryville, Calif.), was also used (10). This assay incorporates recombinant HIV-1 antigens (p24, p31, gp120, and gp41) and HIV-2 antigens (p26 and envelope synthetic peptide).…”

Section: Methodsmentioning

confidence: 99%

Field Evaluation of a Combination of Monospecific Enzyme-Linked Immunosorbent Assays for Type-Specific Diagnosis of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 Infections in HIV-Seropositive Persons in Abidjan, Ivory Coast

et al. 1998

View full text Add to dashboard Cite

Serologic distinction between human immunodeficiency virus type 1 (HIV-1) and HIV-2 infection is made difficult because of the cross-reactivity and high cost of existing differentiation assays. An evaluation of a strategy based on a combination of monospecific enzyme-linked immunosorbent assays (ELISAs) (CME), was carried out in Abidjan, Ivory Coast, where both HIV-1 and HIV-2 are present, to determine its accuracy and cost-effectiveness. A total of 1,608 (428 HIV-1-positive, 361 HIV-2-positive, 371 dually HIV-1 and HIV-2 [HIV-D] reactive, and 448 HIV-negative) sera that had been serotyped by a line immunoassay (Peptilav) were tested retrospectively by an HIV-1-monospecific (Wellcozyme HIV Recombinant ELISA) and an HIV-2-monospecific (ICE*-HIV-2) assay. The CME strategy gave concordant results for all of the 428 sera scored as HIV-1 by Peptilav. Of the 361 sera scored as HIV-2 by Peptilav, 316 (87.5%) were scored as HIV-2 by CME; the remaining 45 sera were positive by both monospecific ELISAs (mean optical density ratios, 1.36 for Wellcozyme and 11.30 for ICE*-HIV-2) and were classified as HIV-D by CME. Of the 371 sera classified as HIV-D by Peptilav, 344 (92.7%), 21, and 6 were scored as HIV-D, HIV-1, and HIV-2, respectively, by CME. Additional testing of the discrepant samples by two HIV differentiation assays (RIBA and INNO-LIA) gave results that agreed with those by CME for most of the sera. In addition, 267 other sera were tested prospectively by both CME and Peptilav. In the prospective evaluation, CME results agreed with those by Peptilav for all 106 HIV-1 sera and 40 of the 41 HIV-2 sera. However, of the 120 sera scored as HIV-D by Peptilav, 69 (57.5%), 47 (39.2%), and 4 (3.3%) were scored as HIV-D, HIV-1 only, and HIV-2 only, respectively, by CME. All 47 samples scored as HIV-1 by CME and two of four HIV-2 sera gave concordant results by RIBA, whereas 29 of 47 sera scored as HIV-1 by CME and all four HIV-2 sera gave concordant results by INNO-LIA. The reagent cost for the CME strategy was 59% lower than the cost of the Peptilav strategy. These results suggest that a combination of highly sensitive and specific commercially available monospecific ELISAs is a reliable and cost-effective strategy for type-specific serodiagnosis of HIV-1 and HIV-2 infections in HIV-seropositive persons and therefore represents a recommended strategy in areas where both HIV-1 and HIV-2 are endemic.

show abstract

“…To determine antibody specificity, both a strip immunoblot assay (SIA) and an immunofluorescence assay (IF) were used. In the SIA [17], the binding specificity of the recombinant anti-HIV-1 scFv was tested with an HIV-1 strip (HIV-1 serum detection Kit, GBI Biotech Corporation, Beijing, China) according to the manufacturers' instructions. Briefly, HIV-1 antigen strips were incubated with 1 ml of recombinant scFv, or control parent mAb, at a concentration of 1 nM (all antibodies were diluted in PBS with 1% skimmed milk).…”

Section: Specificity Determination Of Recombinant Scfvmentioning

confidence: 99%

Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120

Wang

Cole

Jiang

et al. 2005

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe HIV-1 envelope glycoprotein surface subunit gp120 is an attractive target for molecular intervention. This is because anti-HIV-1 gp120 neutralizing antibodies display the potential ability to inhibit HIV-1 infection. The present investigation describes the construction of a genetically engineered single chain antibody (scFv102) against HIV-1 gp120, its expression and functional evaluation. The parental hybridoma cell line (102) produces an immunoglobulin directed against the conserved CD4-binding region of gp120. cDNAs encoding the variable regions of the heavy (V H ) and light (V L ) chains were prepared by reverse transcription PCR and linked together with an oligonucleotide encoding a linker peptide (Gly 4 Ser) 3 to produce a single chain antibody gene. The resulting DNA construct was cloned into a prokaryotic expression vector (pET28) and recombinant scFv102 was expressed in Eserichia coli as an insoluble protein. The denatured scFv102 was refolded and purified by immobilized metal ion affinity chromatography. Purified scFv102 had the same specificity as the intact IgG in immuno-blotting assays and immuno-fluorescence (IF) detection, but ELISA analyses demonstrated the affinity of scFv102 to be 5-fold lower than that of the parental monoclonal antibody. In neutralization assays, scFv102 at concentrations lower than 40 m g/ml exhibited efficient interference with viral replication and inhibition of viral infection (90%) across a range of primary isolates of subtype B HIV-1. These results suggest that the constructed anti-HIV-1 gp120 scFv102 has good biological activity and can potentially be used for in vitro diagnostic and in vivo therapeutic applications.

show abstract

Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay

Cited by 21 publications

References 15 publications

Human immunodeficiency virus in cadavers: A review

Human immunodeficiency virus in cadavers: A review

Field Evaluation of a Combination of Monospecific Enzyme-Linked Immunosorbent Assays for Type-Specific Diagnosis of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 Infections in HIV-Seropositive Persons in Abidjan, Ivory Coast

Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120

Contact Info

Product

Resources

About